Esters News and Research

RSS

Changes in cholesterol metabolism induced by diet can alter the gut flora

For more than half a century, researchers have known that the bacteria that colonize the gastrointestinal tract of mammals influence their host's cholesterol metabolism. Now, Jens Walter and colleagues of the University of Nebraska show that changes in cholesterol metabolism induced by diet can alter the gut flora.

19 Dec 2012

Probiotic formulation can reduce cholesterol esters

Two daily doses of a probiotic lowered key cholesterol-bearing molecules in the blood as well as "bad" and total cholesterol, in a study presented at the American Heart Association's Scientific Sessions 2012.

6 Nov 2012

Links between deodorants and breast cancer refuted but more information needed: Study

A chemical present in cosmetics, food products and pharmaceuticals has been found in tissue samples from 40 women with breast cancer. A number of studies since 1998 have raised concerns about the potential role of these chemicals called parabens in breast cancer as they possess estrogenic properties. Estrogen is known to play a central role in the development, growth and progression of breast cancer.

16 Jan 2012

Omega Protein third quarter revenues increase 28.1% to $71.7 million

Omega Protein Corporation, a nutritional ingredient company and the nation's leading vertically integrated producer of omega-3 fish oil and specialty fish meal products, today reported financial results for the third quarter ended September 30, 2011.

9 Nov 2011

Respiratory problems in homes on the rise due to air freshners

Sales of home air fresheners and scented candles are on the rise and so are respiratory problems in homes where these products are used, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Nov 3-8.

7 Nov 2011

USPTO issues notice of allowance to Cenestra Health's omega-3 fatty acid formulations

The U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance related to Cenestra Health's high-purity omega-3 fatty acid formulations and their methods of use.

19 Sep 2011

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today that their lead program, SBC-102, an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, currently in clinical trials, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).

23 Jun 2011

Trimeris, Synageva enter definitive merger agreement

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, and Trimeris, Inc., announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction.

13 Jun 2011

Exacerbate-reverse' approach can identify potential therapy for fatal childhood disease

Many genes that cause human diseases have parallel genes in other organisms, including yeast. Now Columbia University researchers have used an innovative yeast-based screening method to identify a possible treatment for the fatal childhood disease Niemann-Pick C.

19 Apr 2011

Chemicals lining food wrappers migrating to humans

University of Toronto scientists have found that chemicals used to line junk food wrappers and microwave popcorn bags are migrating into food and being ingested by people where they are contributing to chemical contamination observed in blood.

9 Nov 2010

XenoPort to present XP23829 preclinical data at ECTRIMS meeting

XenoPort, Inc. announced today that it will present data on a new preclinical product candidate, XP23829, at the upcoming 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Gothenburg, Sweden, October 13 - 16, 2010.

14 Oct 2010

RIFM publishes special issue on safety assessment of unsaturated alcohols

The Research Institute for Fragrance Materials, Inc. (RIFM) has now published on the RIFM web site, in the Publications section, a special issue of Food and Chemical Toxicology, Volume 48, Supplement 3, on the RIFM Human Health Group Summary, A Safety Assessment of Non-cyclic Alcohols with Unsaturated Branched Chain when used as Fragrance Ingredients.

4 Sep 2010

Biotage introduces ExploraSep 96-well screening plates to identify optimum scavengers

Biotage, a leading supplier of tools and technology for analytical and medicinal chemistry, announced the introduction of ExploraSep 96-well screening plates to identify optimum scavengers. The 4 different screening plates deliver 128 selective resins based on high-performance, Molecularly Imprinted Polymers (MIPs). Biotage provides professional MIPs technical consultation, information on additional formats as well as assistance with data interpretation and process development.

15 Jul 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.

4 May 2010

Omega-3 fatty acid supplements do not improve levels of depression in heart disease patients

Contrary to the findings of some studies, new research indicates that augmenting antidepressant therapy with an omega-3 fatty acid supplement does not result in improvement in levels of depression in patients with coronary heart disease, according to a study in the October 21 issue of JAMA.

26 Oct 2009

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice

Nanoparticle delivery of diphtheria toxin-encoding DNA that expresses selectively in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect that this therapy could be tested in humans with advanced ovarian cancer within 18 to 24 months, according to a report in Cancer Research. If additional tests are successful, these finding could lead to a new treatment for ovarian cancer, which now causes more than 15,000 deaths each year in the United States. Because it is usually diagnosed at a relatively late stage, ovarian cancer is one of the most deadly forms of the disease.

7 Sep 2009

New nano-gene therapy technique could fight late-stage tumors

Tiny particles carrying a killer gene can effectively suppress ovarian tumor growth in mice, according to a team of researchers from MIT and the Lankenau Institute.

31 Jul 2009

Do omega-3 fatty acids prevent depression in coronary heart disease?

Depression is an established risk factor for the development of coronary heart disease (CHD) in healthy patients and for adverse cardiovascular outcomes in patients with existing CHD. Dietary factors resulting in lower levels of omega-3 fatty acids not only increase CHD risk, but may also be involved in the pathophysiology of depression.

9 Jun 2009

Prion infection of neurons increases the free cholesterol content in cell membranes

A new study published in the online open access journal BMC Biology suggests that disturbances in membrane cholesterol may be the mechanism by which prions cause neurodegeneration and could point to a role for cholesterol in other neurodegenerative diseases.

12 Feb 2008

Isocitric acid from fermentation of sunflower oil - a new building block for pharma?

The citric acid cycle, one of the most important metabolic processes in our bodies, was formulated in 1937. Since then, all of the intermediates have been produced in multigram quantities - with one exception, (2 R,3S)-isocitric acid.

4 Feb 2008